Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.02
0.022.00%
Pre-Market: 6:37 PM EDT
Comments
Loading...
Hoth Therapeutics Analyst Ratings and Price Targets | NASDAQ:HOTH | Benzinga
Hoth Therapeutics Inc has a consensus price target of $6.5 based on the ratings of 7 analysts. The high is $14 issued by EF Hutton on April 27, 2023. The low is $3 issued by Benchmark on October 11, 2024. The 3 most-recent analyst ratings were released by D. Boral Capital on March 10, 2025, March 6, 2025, and March 4, 2025, respectively. With an average price target of $5 between D. Boral Capital, there's an implied 390.20% upside for Hoth Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
HC Wainwright & Co.
Benchmark
EF Hutton
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Hoth Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/10/2025 | Buy Now | 390.2% | D. Boral Capital | Jason Kolbert48% | $5 → $5 | Maintains | Buy | Get Alert |
| 03/06/2025 | Buy Now | 390.2% | D. Boral Capital | Jason Kolbert48% | $5 → $5 | Maintains | Buy | Get Alert |
| 03/04/2025 | Buy Now | 390.2% | D. Boral Capital | Jason Kolbert48% | $5 → $5 | Maintains | Buy | Get Alert |
| 02/11/2025 | Buy Now | 390.2% | D. Boral Capital | Jason Kolbert48% | $5 → $5 | Maintains | Buy | Get Alert |
| 01/23/2025 | Buy Now | 292.16% | HC Wainwright & Co. | Raghuram Selvaraju43% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | 390.2% | D. Boral Capital | Jason Kolbert48% | $5 → $5 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | 390.2% | D. Boral Capital | Jason Kolbert48% | $5 → $5 | Maintains | Buy | Get Alert |
| 11/04/2024 | Buy Now | 292.16% | HC Wainwright & Co. | Raghuram Selvaraju43% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | 292.16% | HC Wainwright & Co. | Raghuram Selvaraju43% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 10/11/2024 | Buy Now | 194.12% | Benchmark | Bruce Jackson42% | $3 → $3 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 09/05/2024 | Buy Now | 390.2% | EF Hutton | Jason Kolbert48% | $5 → $5 | Maintains | Buy | Get Alert |
| 08/21/2024 | Buy Now | 390.2% | EF Hutton | Jason Kolbert48% | $5 → $5 | Assumes | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | 292.16% | HC Wainwright & Co. | Raghuram Selvaraju43% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2024 | Buy Now | 292.16% | HC Wainwright & Co. | Raghuram Selvaraju43% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 07/22/2024 | Buy Now | 292.16% | HC Wainwright & Co. | Raghuram Selvaraju43% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | Buy Now | 292.16% | HC Wainwright & Co. | Raghuram Selvaraju43% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | Buy Now | 586.27% | EF Hutton | Tim Moore54% | $6.5 → $7 | Maintains | Buy | Get Alert |
| 02/05/2024 | Buy Now | 292.16% | HC Wainwright & Co. | Raghuram Selvaraju43% | → $4 | Initiates | → Buy | Get Alert |
| 09/14/2023 | Buy Now | 635.29% | EF Hutton | Elemer Piros55% | $12 → $7.5 | Maintains | Buy | Get Alert |
| 08/23/2023 | Buy Now | 1272.55% | EF Hutton | Elemer Piros55% | → $14 | Assumes | → Buy | Get Alert |
| 06/20/2023 | Buy Now | 390.2% | Benchmark | Bruce Jackson42% | → $5 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 06/01/2023 | Buy Now | 1272.55% | EF Hutton | Elemer Piros55% | → $14 | Assumes | → Buy | Get Alert |
| 04/27/2023 | Buy Now | 1272.55% | EF Hutton | Constantine Davides38% | → $14 | Reiterates | → Buy | Get Alert |
| 04/10/2023 | Buy Now | 390.2% | Benchmark | Bruce Jackson42% | → $5 | Reiterates | → Speculative Buy | Get Alert |
| 04/03/2023 | Buy Now | 1272.55% | EF Hutton | Constantine Davides38% | $33 → $14 | Maintains | Buy | Get Alert |
| 12/30/2022 | Buy Now | 3135.29% | EF Hutton | Constantine Davides38% | $45 → $33 | Maintains | Buy | Get Alert |
| 03/31/2022 | Buy Now | 145.1% | EF Hutton | Constantine Davides38% | $68.75 → $62.5 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Hoth Therapeutics (HOTH) stock?
The latest price target for Hoth Therapeutics (NASDAQ:HOTH) was reported by D. Boral Capital on March 10, 2025. The analyst firm set a price target for $5.00 expecting HOTH to rise to within 12 months (a possible 390.20% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Hoth Therapeutics (HOTH)?
The latest analyst rating for Hoth Therapeutics (NASDAQ:HOTH) was provided by D. Boral Capital, and Hoth Therapeutics maintained their buy rating.
When was the last upgrade for Hoth Therapeutics (HOTH)?
There is no last upgrade for Hoth Therapeutics
When was the last downgrade for Hoth Therapeutics (HOTH)?
There is no last downgrade for Hoth Therapeutics.
When is the next analyst rating going to be posted or updated for Hoth Therapeutics (HOTH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hoth Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hoth Therapeutics was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.
Is the Analyst Rating Hoth Therapeutics (HOTH) correct?
While ratings are subjective and will change, the latest Hoth Therapeutics (HOTH) rating was a maintained with a price target of $5.00 to $5.00. The current price Hoth Therapeutics (HOTH) is trading at is $1.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.